Выбор фиксированной комбинации у пациентов с артериальной гипертонией: фокус на антигипертензивные и нефропротективные свойства фиксированной комбинации лизиноприла и амлодипина (клинический пример)

Артериальная гипертензия (АГ) остается одной из самых значимых медико-социальных проблем в мире, ее распространенность среди взрослого населения составляет 30–45%. Наряду с этим современное население характеризуется высокой заболеваемостью хронической болезнью почек (ХБП), в том числе за счет их вторичного поражения в рамках АГ. В свою очередь, ХБП является важным независимым фактором риска развития и прогрессирования сердечно-сосудистых заболеваний, в том числе фатальных. Использование при лечении пациентов с АГ имеющихся подходов к нефропротекции позволит существенно улучшить прогноз как у больных с факторами риска развития почечной дисфункции, так и у пациентов с уже имеющимся заболеванием почек. Согласно современным рекомендациям по АГ в таких клинических ситуациях следует начинать терапию с фиксированных комбинаций антигипертензивных препаратов. Наибольшую эффективность, согласно данным доказательной медицины у больных с АГ высокого риска, в том числе и с позиций нефропротекции, продемонстрировала комбинация ингибитора ангиотензинпревращающего фермента (ИАПФ) и дигидропиридинового блокатора кальциевых каналов (БКК). В представленном клиническом случае описано успешное применение фиксированной комбинации ИАПФ и БКК у пациента с АГ и микроальбуминурией.

артериальная гипертензия, хроническая болезнь почек, микроальбуминурия, клинический случай, антигипертензивная терапия, фиксированные комбинации антигипертензивных препаратов, лизиноприл, амлодипин

1. Муромцева Г. А., Концевая А. В., Константинов В. В., Артамонова Г. В., Гатагонова Т.М., Дупляков Д. В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012–2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014; 13 (6р): 4–11. http://dx.doi.org/10.15829/1728–8800–2014–6–4–11.

2. Бойцов С. А., Баланова Ю. А., Шальнова С. А., Деев А. Д. Артамонова Г. В., Гатагонова Т.М. и др. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014; 4: 4–14. doi.org/10.15829/1728–8800–2014–44–14 https://doi.org/10.15829/1728–8800–2014–4–4–14].

3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365: 217–223. DOI: 10.1016/S0140–6736(05)17741–1.

4. Franklin SS, Lopez VA, Wong ND, Mitchell GF, Larson MG, Vasan RS et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation. 2009; 119: 243–250. https://doi. org/10.1007/978–1–4471–5198–2_20.

5. Williams B, Mancia G, Spiering W Rosei AA, Azizi M, Burnier M, et al. 2018. ESC/ ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018; 36 (10): 1953–2041. DOI: 10.1097/HJH.0000000000002017.

6. Артериальная гипертензия у взрослых. Клинические рекомендации по артериальной гипертензии 2020. Министерство здравоохранения Российской Федерации. Российское Кардиологическое общество. Https://Scardio.Ru/ Content/Guidelines/Clinic_Rek_AG_2020.pdf.

7. Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Pedersen C et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J. 2010; 31: 883–891. https://doi.org/10.1007/ s40292–016–0139–2.

8. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H et al. Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts. J Hypertens. 2012; 30: 1928–1936. https://doi.org/10.1007/978–3–319–75310–2_8.

9. Volpe M, Battistoni A, Tocci G, Agabiti Rosei E, Catapano AL, Coppo R et al. Cardiovascular risk assessment beyond systemic coronary risk estimation: a role for organ damage markers. J Hypertens. 2012; 30: 1056–1064. https://doi. org/10.1097/HJH.0b013e3283525715.

10. Clase CM, Garg AX, Kiberd BA. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANESIII). J Am Soc Nephrol. 2002; 13 (5): 1338–1349. DOI: 10.1097/01. asn.0000013291.78621.26.

11. McCullough PA, Li S, Jurkovitz CT, Stevens LA, Wang C, Collins AJ et al. CKD and cardiovascular disease in screened highrisk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis. 2008; 51 (2): 38–45. DOI: http://dx.doi.org/10.5888/pcd10.110339.

12. Sarafidis PA, Li S, Chen SC. Hypertension awareness, treatment, and control in chronic kidney diseseas. Am. J. Med. 2008; 121: 332–340. DOI: 10.1016/j.amjmed.2007.11.025.

13. Kalaitzidis RG, Bakris GL. Prehypertension: is it relevant for nephrologists? Kidney Int. 2010; 77: 194–200. DOI: 10.1038/ki.2009.439.

14. Подзолков В.И., Брагина А.Е., Ишина Т.И., Брагина Г.И., Васильева Л.В. Нефропротективная стратегия в лечении артериальной гипертензии как современная общемедицинская задача. Российский кардиологический журнал. 2018; 23 (12): 107–118. http://dx.doi.org/10.15829/1560–4071–2018–12–107–118

15. Matsushita K, Mahmodi BK, Woodward M, Emberson JM, Jafar JH, Jee SH et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estmated glomerular filtration rate. JAMA. 2012; 307: 1941–1951. DOI: 10.1001/jama.2012.3954.

16. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K. Definition, evaluation and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69: 1945–1953. https://doi.org/10.1038/sj.ki.5000414.

17. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Executive summary. Am J Kid Dis. 2004; 43 (1): 16–33. DOI: 10.1053/j.ajkd.2004.03.003.

18. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002; 106: 1777–1782. DOI: 10.1161/01. cir.0000031732.78052.81.

19. Karalliedde J, Viberti G. Microalbuminuria and cardiovascular risk. Am J Hypertens. 2004; 17: 986–93. DOI: 10.1016/j.amjhyper.2004.08.010.

20. Pedrinelli R, Dell’Omo G, Di Bello V, Pontremoli R, Mariani M. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens. 2002; 16: 79–89. DOI: 10.1038/sj.jhh.1001316.

21. Rein P, Boehnel C, Vonbank A, Saely CH, Beer S, Jankovic V et al. Albuminuria is associated with angiographically determined coronary atherosclerosis both in patients with type 2 diabetes and in non-diabetic individuals. European Heart Journal. 2010; 31: 802. DOI: 10.1016/j.amjcard.2010.12.011.

22. Wachtell K, Ibsen H, Olsen MH, Lars L, Dahlöf B, Devereux B, Kjeldsenet R et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003; 139: 901–906. DOI: 10.1097/01. hjh.0000217862.50735.dc.

23. Klausen K, Scharling H, Jensen J. Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases. Intern. Med. 2006; 260 (3): 231–237. DOI: 10.1111/j.1365–2796.2006.01679.x.

24. Сорокин Е. В. Сердечно-сосудистые заболевания, микроальбуминурия и статины: ожидается ли новый прорыв? Русский медицинский журнал. [Дата обращения 06.07.2020]. https://www.rmj.ru/articles/kardiologiya/Serdechnososudistye_zabolevaniya__mikroalybuminuriya_i_statiny__oghidaetsya_li_novyy_proryv/#ixzz6RjqYjPGl https://www.rmj.ru/articles/kardiologiya/Serdechnososudistye_zabolevaniya__mikroalybuminuriya_i_statiny__oghidaetsya_li_novyy_proryv/#ixzz6RjqYjPGl].

25. Klausen K, Johnsen KB, Rasmussen F, Jensen G, Clausen P, Scharling H et al. Very low levels of microalbuminuria are associated with an increased risk of coronary heart disease and death independent of renal function, hypertension, and diabetes. Am Heart Association. 2004; 110: 32–35. DOI: 10.1161/01. CIR.0000133312.96477.48.

26. De Leeuw PW, Ruilope LM, Palmer CR, Brown MJ, Castaigne A, Mancia G, et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med. 2004; 164: 2459–64. DOI: 10.1001/ archinte.164.22.2459.

27. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol. 200; 12: 218–225. DOI: 10.1097/HJH.0b013e328133246c.

28. De Leeuw PW, Thijs L, Birkenhager WH, Voyaki SM, Efstratopoulos AD, Fagard RH, et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol. 2002; 13: 2213–2222. DOI: 10.1001/archinte.164.22.2459.

29. Segura J, Ruilope LM, Zanchetti A. On the importance of estimating renal function for cardiovascular risk assessment. J Hypertens. 2004; 23: 1635–1639. DOI: 10.1093/ndt/gfk025.

30. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med. 2006; 144: 172–180. DOI: 10.7326/0003– 4819–144–3–200602070–00005.

31. Matsushita K, Woodward M, Mahmoodi BK, Emberson JR. Comparison of risk prediction using the CKDEPI equation and the MDRD study equation for estimated glomerular filtration rate. JАMA. 2012. 307 (18): 1941–51. DOI: 10.1001/ jama.2012.3954.

32. Rosenberg WM, Gray JA, Brian HR, Scott RW. Evidence based medicine: what it is and what it isn»t. BMJ. 1996; 312 (7023): 71–72. DOI: https://doi.org/10.1136/ bmj.312.7023.71.

33. Федеральный закон «Об основах охраны здоровья граждан в Российской Федерации» (от 21.11.2011 № 323-ФЗ, ред. от 03.04.2017 https://minzdrav.gov.ru/documents/7025].

34. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, deJong PE et al. AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003; 139: 244–52. DOI: 10.7326/0003–4819–139– 4–200308190–00006.

35. Sim JJ, Shi J, Kovesdy CP, Kalantar-Zadeh K, Jacobsen SJ. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol. 2014; 64: 588–597. DOI: 10.1016/j.jacc.2014.04.065.

36. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet. 2007; 369: 1208–1219. DOI: 10.1016/S 0140– 6736(07)60242–6.

37. Kunz R, Friedrich C, Wolbers M, Mann JF. Metaanalysis: effect of monotherapy and combination therapy with inhibitors of the rennin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30–48. DOI: 10.7326/0003– 4819–148–1–200801010–00190.

38. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011; 364: 907–917. DOI: 10.1056/NEJMoa1007994.

39. Ruggenenti P, Fassi A, Ilieva AP, Iliev IP, Chiurchiu C, Rubis N, et al. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. J Hypertens. 2011; 29: 207–216. DOI: 10.1056/NEJMoa042167.

40. Драпкина О.М., Елиашевич С.О. Оптимальные союзники в стратегии контроля уровня артериального давления. Кардиология. 2015; 55 (3): 106–147. DOI: https://dx.doi.org/10.18565/cardio.2015.3.106–114. https://dx.doi.org/10.18565/cardio.2015.3.106–114].

41. Bakris GL, Sarafidis PA, Weir MR Dahlöf B, Pitt B, Jamerson K et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010; 375 (9721): 1173–1181. DOI: 10.1016/S0140–6736 (09)62100–0.

42. Leoncini G, Martinoli C, Viazzi F, Maura Ravera, Denise Parodi, Elena Ratto et al. Changes in renal resistive index and urinaryalbumin excretion in hypertensivepatients under long-term treatment withlisinopril or nifedipine GITS. Nephron. 2002; 90 (2): 169–173. DOI: 10.1159/000049038.

43. Holdaas H, Hartmann A, Lien MG, Nilsen L. Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Intern Med. 1991; 229 (2): 163–170. DOI: 10.1111/ j.1365–2796.1991.tb00325.x.

44. ODonnell MJ, Rowe BR, Lawson N, Horton A, Gyde OH, Barnett AH. Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomized double-blind study. J Hum Hypertens. 1993; 7 (4): 333–339. DOI: 10.1007/978–1–4757–6749–0_36.

45. Шестакова М.В., Викулова О.К. Клиническая эффективность лизиноприла при диабетической нефропатии. Русский медицинский журнал. 2005; 13 (28): 1952–1955

46. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy. J Diabetes Complications. 1996; 10 (3): 133–135. DOI: 10.1136/ bmj.294.6585.1443.

47. Chaturvedi N, Stevenson J, Fuller JH, Rottiers R, Ferriss B. Randomised placebo controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet. 1997; 349: 1787–1792.

48. Parving H-H: Initiation and progression of diabetic nephropathy. N Engl J Med. 1996; 335: 1682–1683. DOI: 10.1056/NEJM199611283352212.

49. Chaturvedi N, Stevenson J, Fuller JH, Rottiers R, Ferriss B. Randomised placebo controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet. 1997; 349: 1787–1792.

50. Sadat-Ebrahimi SR, Parnianfard N, Vahed N, Babaei H, Ghojazadeh M, Tang S, Azarpazhooh Amir. An evidence-based systematic review of the off-label uses of Lisinopril. British Journal of Clinical Pharmacology. 2018; 84: 2502–2251. DOI: 10.1111/bcp.13705.

51. Janssen JM, Gans RO, Van Der Meulen J, Pijpers R, Ter Wee PM. Comparison between the effects of amlodipine and lisinopril on proteinuria in nondiabetic renal failure a double-blind, randomized prospective study. Am J Hypertens. 1998; 11: 1074–1079.

52. Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS, Parving HH. Differences between Nisoldipine and Lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes. 1997; 46: 481–487. DOI: 10.2337/diab.46.3.481.

53. Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH. Longterm renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2000; 23: 1725–1730. https://doi.org/10.2337/ diacare.23.12.1723.

54. Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care. 1998; 21: 104–110. DOI: 10.2337/diacare.21.1.104.

55. Асташкин Е.И., Глезер М. Г. Механизмы комбинированного действия ингибиторов ангиотензин-превращающего фермента и антагонистов кальция при артериальной гипертонии. Кардиоваскулярная терапия и профилактика. 2013; 12 (3): 72–77. https://doi.org/10.15829/1728–8800–2013–3–72–77. https://doi.org/10.15829/1728–8800–2013–3–72–77].

56. Ranieri G, Andriani A, Lamontanara G, Cesaris RD. Effects of lisinopril and amlodipine on microalbuminuria and renal function in patients with hypertension. Clin Pharmacol Ther. 1994; 56: 323–330. DOI: 10.1038/clpt.1994.143.

57. Poulsen PL, Ebbehøj E, Mogensen CE. Lisinopril reduces albuminuria during exercise in low grade microalbuminuric type 1diabetic patients: a double blind randomized study. J Intern Med. 2001; 249: 433–440. DOI: 10.2337/diab.43.10.1248.

58. Nielsen FS, Rossing P, Gall M-A, Skott P, Smidt UM, Parving HH. Long-term effect of Lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes. 1997; 46: 1182–1188. DOI: 10.2337/diab.46.7.1182.

59. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000; 321: 1440–1444. DOI: https://doi.org/10.1136/bmj.321.7274.1440.

60. Laverman GD, Navis G, Henning RH, De Jong PE, De Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. 2002; 62: 1020–1025. http://dx.doi.org/10.1053/ajkd.2001.29262.

61. Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, et al. An evidence-based systematic review of the off-label uses of lisinopril. Pharmacology Br J Clin Pharmacol. 2018; 84: 2502–21. DOI: 10.1111/bcp.13705.

62. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000; 102: 1388–1393. DOI: 10.1161/01.cir.102.12.1388.